A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study
| Autor: | H. de Graaf, M. Polee, Anna K.L. Reyners, Willem M. Smit, A.N.M. Wymenga, Pax H.B. Willemse, Frans L. G. Erdkamp, M A T M van Vugt, Roy I. Lalisang, L. de Munck, K. Hoekman, Michael Schaapveld, Harry Hollema |
|---|---|
| Přispěvatelé: | MUMC+: MA Medische Oncologie (9), Interne Geneeskunde, RS: GROW - School for Oncology and Reproduction, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Targeted Gynaecologic Oncology (TARGON), Medical oncology, CCA - Innovative therapy |
| Rok vydání: | 2012 |
| Předmět: |
Oncology
epithelial ovarian cancer randomized phase II study Phases of clinical research Carcinoma Ovarian Epithelial PACLITAXEL chemistry.chemical_compound Antineoplastic Combined Chemotherapy Protocols Medicine docetaxel Neoplasms Glandular and Epithelial Peritoneal Neoplasms INTERGROUP Aged 80 and over Ovarian Neoplasms RISK Sulfonamides celecoxib WOMEN Hematology Middle Aged Chemotherapy regimen CYCLOOXYGENASE-2 EXPRESSION Tolerability Docetaxel carboplatin COX-2 inhibitor Female Taxoids TRIAL medicine.drug Adult medicine.medical_specialty DOXORUBICIN CELL LUNG-CANCER Disease-Free Survival CISPLATIN Internal medicine Fallopian Tube Neoplasms Humans neoplasms Aged Neoplasm Staging Cyclooxygenase 2 Inhibitors business.industry medicine.disease Carboplatin first-line chemotherapy chemistry Celecoxib Pyrazoles business Ovarian cancer |
| Zdroj: | Annals of Oncology, 23(11), 2896-2902. Oxford University Press Reyners, A K L, de Munck, L, Erdkamp, F L G, Smit, W M, Hoekman, K, Lalisang, R I, de Graaf, H, Wymenga, A N M, Polee, M, Hollema, H, van Vugt, M A T M, Schaapveld, M & Willemse, P H B 2012, ' A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study ', Annals of Oncology, vol. 23, no. 11, pp. 2896-2902 . https://doi.org/10.1093/annonc/mds107 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mds107 |
| Popis: | In ovarian cancer, cyclooxygenase-2 (COX-2) overexpression is prognostic for poor survival. We investigated the efficacy of celecoxib (C), a selective COX-2 inhibitor, added to docetaxel (Taxotere)/carboplatin (DC) in advanced ovarian cancer.In a phase II, randomized study, 400 mg celecoxib b.i.d. was added to first-line DC treatment (DCC). Celecoxib was to be continued after DC termination up to 3 years. Study end points were tolerability, progression-free survival (PFS) and overall survival (OS).151 of 196 eligible patients were diagnosed with stage IIIC/IV disease. Median follow-up for patients alive was 32.3 months. Celecoxib was used during a mean of 8.5 months. Twenty-three of 97 DCC patients stopped celecoxib prematurely, mainly due to skin reactions. Complete biochemical response was achieved in 51/78 DC patients (65%) versus 57/78 DCC patients (75%, not significant). In both study arms, median PFS was 14.3 months and median OS 34 months. COX-2 was expressed in 82% of 120 tumor samples retrospectively recovered. The PFS and OS of patients with intermediate/high COX-2 expression were similar to that in the other patients.Celecoxib did not influence PFS and OS, but interpretation of results is hampered by premature celecoxib discontinuation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|